New drug combo shows early promise in Hard-to-Treat cancers

NCT ID NCT05162755

Completed Disease control Sponsor: Institut de Recherches Internationales Servier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new drug called S095029, alone and combined with another drug (Sym021), in 41 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and side effects. The study was stopped early for business reasons, not due to safety concerns, so we don't yet know if the combination works well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: S095029 (a drug that targets NKG2A) and Sym021 (a drug that targets PD-1)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 41 participants, so it is primarily testing safety, not effectiveness. The expansion part was stopped early for business reasons, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Princess Margaret Cancer Centre

Toronto, Canada
START Midwest

Grand Rapids, Michigan, 49546, United States
The START Center for Cancer Care

San Antonio, Texas, 78229, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.